Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Follicular
Conditions
Lymphoma, Follicular
Trial Timeline
Jul 14, 2014 → Dec 29, 2018
NCT ID
NCT02162771About Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone
Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone is a phase 3 stage product being developed by Celltrion for Lymphoma, Follicular. The current trial status is completed. This product is registered under clinical trial identifier NCT02162771. Target conditions include Lymphoma, Follicular.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02162771 | Phase 3 | Completed |
Competing Products
20 competing products in Lymphoma, Follicular
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFM13 | Affimed | Phase 2 | 44 |
| Pirtobrutinib + Brexucabtagene Autoleucel | Eli Lilly | Phase 2 | 52 |
| Enzastaurin | Eli Lilly | Phase 2 | 52 |
| Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone | Eli Lilly | Phase 2 | 52 |
| Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) | Eli Lilly | Phase 2 | 52 |
| VIP152 + BTKi | Vincerx Pharma | Phase 1 | 25 |
| Tomivosertib (eFT-508) | eFFECTOR Therapeutics | Phase 1/2 | 33 |
| Nanatinostat in combination with valganciclovir | Viracta Therapeutics | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| Copanlisib + Rituximab | Celltrion | Phase 2 | 52 |
| Rituximab + Pembrolizumab | Celltrion | Phase 2 | 52 |
| Rituximab + Methotrexate + Cytarabine Injection | Celltrion | Phase 2 | 52 |
| rituximab | Celltrion | Phase 1 | 33 |
| CT-P10 + Rituxan | Celltrion | Phase 3 | 77 |
| Rituximab, lenalidomide | Celltrion | Phase 2 | 52 |
| Rituximab + Lenalidomide + Valemetostat | Daiichi Sankyo | Phase 1/2 | 41 |
| Valemetostat tosylate | Daiichi Sankyo | Phase 2 | 52 |
| PLX3397 | Daiichi Sankyo | Phase 2 | 52 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| HMPL-689 | HUTCHMED | Phase 1 | 28 |
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85